FemTech Association Asia’s Post

#breakthrough #pharmanews #womenhealth Qvin™ Introduces Q-Pad™: Transforming Women's Health with FDA-Cleared Lab Testing using Menstrual Blood Qvin, a biotechnology research company, has developed the Q-Pad, a healthcare service that collects menstrual blood samples as an alternative to traditional blood draws. The Q-Pad recently received FDA clearance to measure A1c, an important biomarker for diabetes. It can also test for #diabetes, #anaemia, #fertility #perimenopause, #endometriosis, and #thyroidhealth With the first-ever FDA-cleared menstrual blood health test, Qvin is paving the way to important new opportunities for women's health and this is just the beginning! #opportunities #healthcareinnovation

🔬 Gynaecomastia in children from Lavender and Tea Tree Oil - Insights from EADV 🔬 During the recent EADV conference, new findings were presented on the link between the use of lavender lotion and tea tree oil and the development of prepubertal gynaecomastia. Research suggests that certain essential oils like lavender and tea tree oil contain compounds that act as endocrine disruptors, mimicking estrogen and inhibiting androgen activity. This hormonal imbalance can lead to the development of gynaecomastia, particularly in young boys and adolescents. Key Takeaways: Lavender and Tea Tree Oils – These oils contain phytoestrogens and other active ingredients that may interfere with hormone regulation. Clinical Cases – Numerous case studies have shown a link between the regular use of these oils and hormonal imbalance, leading to breast tissue growth in males. Reversibility – The positive side is that this condition is often reversible upon discontinuation of the products containing these oils. Dermatologist Awareness – It’s important for dermatologists to be aware of these risks and educate patients, especially parents, on the potential effects of products that seem otherwise benign.🧴 #EADV

𝐁𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥 𝐕𝐚𝐠𝐢𝐧𝐨𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐢𝐧𝐠 𝐖𝐨𝐦𝐞𝐧'𝐬 𝐇𝐞𝐚𝐥𝐭𝐡 𝐰𝐢𝐭𝐡 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨: https://lnkd.in/eZcthd7g As awareness of women's health issues continues to rise, the Bacterial Vaginosis (BV) market is gaining significant attention for providing critical treatments in reproductive health. Bacterial vaginosis, a common yet under-discussed condition, affects millions of women worldwide, and the healthcare industry is responding with innovative solutions. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬: Rising Awareness: Increasing initiatives to raise awareness about women’s reproductive health is boosting demand for effective BV diagnostics and treatments. Advances in Therapeutics: The market is witnessing the development of more effective and accessible antibiotics, probiotics, and non-antibiotic treatments to reduce recurrence rates and improve patient outcomes. Technology Integration: Digital health platforms are playing a vital role in offering easier access to treatment, telemedicine consultations, and improved patient education. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: North America leads the market due to strong healthcare infrastructure and higher awareness, while Asia-Pacific is experiencing rapid growth driven by increasing healthcare accessibility. Why It Matters: With BV linked to increased risks of preterm birth and other complications, it’s essential to focus on early detection and effective treatment. As research advances, the BV market is poised to address this widespread condition with more targeted, patient-friendly therapies. Looking Ahead: Innovations in personalized medicine and microbiome-targeted therapies hold the promise of reshaping the treatment landscape for bacterial vaginosis, offering a better quality of life for millions of women globally. #BacterialVaginosis #WomensHealth #HealthcareInnovation #ReproductiveHealth #MedicalResearch #MarketTrends #Pharmaceuticals #PatientCare #HealthAwareness

Check out the latest report from IMIR Market Research Pvt. Ltd.  on the 𝗪𝗼𝗺𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Women's Health Diagnostics Market Size, Share & Trends Analysis Report By Device Type (Biopsy Devices, Imaging & Monitoring Systems [Ultrasound Devices, Mammography Systems, MRI Systems, Others], Kits & Reagents, Consumable & Accessories), By Test Type (Brest cancer testing, Cervical cancer testing, Prenatal genetic screening & carrier testing, Pregnancy testing, Fertility & ovulation testing, Infection disease testing, Others), By End User (Hospital, Diagnostic laboratories & imaging centers, Specialty clinics, Others), Covid-19's Impacts, Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dBqtrdph 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Abbott AccuBioTech Co., Ltd. Agilent Technologies. Alere Inc.. BD Bio-Rad Laboratories. bioMérieux Cardinal Health. Carestream Chembio Diagnostics, Inc. Cook Medical. Danaher Corporation. Dialab GmbH EKF DIAGNOSTICS HOLDINGS PLC Exact Sciences. F. Hoffmann-La Roche Ltd. FUJIFILM Corporation. GE HealthCare Guided Therapeutics, Inc. Hologic, Inc.. Illumina. Invitae. MANKIND PHARMA LTD MedGyn Products, Inc. Myriad Genetics. Natera. Neurológica Nova Biomedical OSI Systems. Osteometer MediTech, Inc. PerkinElmer. Procter & Gamble. QIAGEN Quest Diagnostics QuidelOrtho. SEKISUI Diagnostics Siemens AG SuperSonic Imagine #womenhealth #health #women #healthylifestyle #fitness #womenempowerment #wellness #womenhealthcare #pcos #fertility #weightloss #healthyfood #selfcare #love #menhealth #motivation #healthy #pregnancy #healthcare #healthyliving #menstrualcramps #endometriosis #vaginalhealth #yonisteam #periodproblems #womenshealth #womensupportingwomen #menstruation #infertility #fibroid

🌟 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐢𝐧 𝐏𝐂𝐎𝐒 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝 𝐨𝐟 𝐰𝐨𝐦𝐞𝐧'𝐬 𝐡𝐞𝐚𝐥𝐭𝐡! 🌟 The Indian Council of Medical Research (ICMR) is set to study the efficacy of Metformin and Inositol in treating Polycystic Ovary Syndrome (PCOS). This research is crucial as PCOS affects a significant number of women globally, leading to various health issues. At "𝐢𝐧 𝐲𝐨𝐮", we are proud to highlight that our product, ‘𝐁𝐚𝐥𝐚𝐧𝐜𝐞 𝐢𝐧 𝐲𝐨𝐮’, focuses on 𝐈𝐧𝐨𝐬𝐢𝐭𝐨𝐥, a key ingredient known for its remarkable benefits in PCOS management.   𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐈𝐧𝐨𝐬𝐢𝐭𝐨𝐥 𝐢𝐧 𝐏𝐂𝐎𝐒: - 𝑰𝒎𝒑𝒓𝒐𝒗𝒆𝒔 𝑰𝒏𝒔𝒖𝒍𝒊𝒏 𝑺𝒆𝒏𝒔𝒊𝒕𝒊𝒗𝒊𝒕𝒚: Inositol enhances cellular response to insulin, helping to manage blood sugar levels effectively. - 𝑹𝒆𝒅𝒖𝒄𝒆𝒔 𝑨𝒏𝒅𝒓𝒐𝒈𝒆𝒏 𝑳𝒆𝒗𝒆𝒍𝒔: It aids in lowering testosterone and androstenedione levels, which can alleviate symptoms like excess hair growth and acne. - 𝑹𝒆𝒈𝒖𝒍𝒂𝒕𝒆𝒔 𝑴𝒆𝒏𝒔𝒕𝒓𝒖𝒂𝒍 𝑪𝒚𝒄𝒍𝒆𝒔: Inositol has been shown to restore regular menstrual cycles, promoting ovulation and improving fertility outcomes. - 𝑬𝒏𝒉𝒂𝒏𝒄𝒆𝒔 𝑭𝒆𝒓𝒕𝒊𝒍𝒊𝒕𝒚: Research indicates that Inositol can improve ovarian function and fertility rates in women with PCOS. - 𝑺𝒖𝒑𝒑𝒐𝒓𝒕𝒔 𝑾𝒆𝒊𝒈𝒉𝒕 𝑴𝒂𝒏𝒂𝒈𝒆𝒎𝒆𝒏𝒕: Studies indicate that Inositol can contribute to weight loss, which is often a challenge for women with PCOS. 𝐇𝐨𝐰 𝐝𝐨𝐞𝐬 𝐢𝐧𝐨𝐬𝐢𝐭𝐨𝐥 𝐦𝐚𝐲 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐭𝐡𝐞 𝐜𝐡𝐚𝐧𝐜𝐞𝐬 𝐨𝐟 𝐜𝐨𝐧𝐜𝐞𝐩𝐭𝐢𝐨𝐧? Inositol has been shown to 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝘀𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆 𝗮𝗻𝗱 𝗿𝗲𝗱𝘂𝗰𝗲 𝗵𝘆𝗽𝗲𝗿𝗮𝗻𝗱𝗿𝗼𝗴𝗲𝗻𝗮𝗲𝗺𝗶𝗮 in women with PCOS. These improvements may lead to more 𝗿𝗲𝗴𝘂𝗹𝗮𝗿 𝗼𝘃𝘂𝗹𝗮𝘁𝗶𝗼𝗻, which can increase the chances of conception. Additionally, inositol may enhance the quality of oocytes, further contributing to fertility. 𝗔𝘀 𝘄𝗲 𝗮𝘄𝗮𝗶𝘁 𝘁𝗵𝗲 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗳𝗿𝗼𝗺 𝗜𝗖𝗠𝗥, we remain committed to empowering women through effective solutions!! 💪✨ Source: https://lnkd.in/gV-dnhMx Product link: https: //https://lnkd.in/ga_P8Nce in you AJEET CHAUHAN Sunil Sreekakula Vaibhav Garg CA Ashish Sharma #PCOS #Inositol #Research #WomensHealth #Balance #InYou #BalanceInYou #ICMR

Toward advancement of women's health; I am pleased to share our research paper titled "A Novel Intrauterine Device for the Spatio-Temporal Release of Norethindrone Acetate as a Counter-Estrogenic Intervention in the Genitourinary Syndrome of Menopause" in the Journal of Pharmaceutics. The utilization of progestogens offers a means to counteract the effects of estrogen on the endometrial tissue, decreasing unwanted side effects and improving therapeutic outcomes. In this study, a norethindrone acetate (NETA)-loaded, hollow, cylindrical, and sustained release platform has been designed, fabricated, and optimized for implantation in the uterine cavity as a counter-estrogenic intervention in the treatment of GSM. The significant findings of this study firmly establish the developed platform as a promising candidate for the sustained release of NETA within the uterine cavity. This functionality serves as a counter-estrogenic intervention in the treatment of GSM, with the platform holding potential for further advanced biomedical applications. I have the pleasure of being under the supervision of Dr. Mershen Govender, Prof. Pradeep Kumar, and Prof. Yahya Choonara on this project, and it is an honor to work with them. Lastly, I would like to recommend the paper to broaden your horizons in this field 👇 : https://lnkd.in/dmtKcPEh #design #pharmaceutics #waddp

How is biotech pioneering new patient options for endometriosis? 🚀 Affecting around 190 million women and girls, endometriosis is a condition that has been rather difficult to treat with no cures to date. 📅 It is caused by the growth of tissue outside the uterus, leading to debilitating pelvic pain during sex and heavy periods. With some clinical trials showing promise and with the discovery of new drug targets, there is hope for better endometriosis care. 💊 Read our latest article to find out about some of the recent advancements in endometriosis research! 👇 https://lnkd.in/dXAXCu7w #endometriosis #biotechinnovation #womenshealth #clinicaltrials #medicalresearch #healthcareinnovation #biotechnews Bruce Nicholson | Hera Biotech | The University of Edinburgh | TiumBio | Serac Healthcare | Western Sydney University | FimmCyte | Celmatix

Sneaking in a #WomensHealthWednesday before the day officially runs out. The future of women’s health will undoubtedly include more non-invasive #diagnostics. The future is one step closer with this week’s FDA clearance of Qvin Q-pad which uses #menstrual blood collected on a testing strip built into a menstrual pad and will allow #diabetic women to non-invasively monitor #HbA1c. https://lnkd.in/e8npQaGZ A1c has traditionally required a finger stick and doctor or lab visit. This new product eliminates both the pain and the hassle. The Q-Pad strip will be sent to a #CLIA certified lab and the patient will receive their result via the Qvin app. For diabetics, A1c is a measure of trailing 3 months of blood glucose levels. This first application, and the need to send to a lab, may not be transformational, but it is the first step to more impactful patient care. In fact, we reported half a year ago in another #WHW post that researchers had recently correlated endometrial tissue shed into period blood as being distinct in patients with endometriosis vs in patients without it. https://lnkd.in/eNNHiz_f  A non-invasive diagnostic test for #endometriosis continues to be one of the holy grails of women’s health. It is this very combination of basic science research and product innovation that our industry needs and that we hope the recent The White House Women's Health Initiative will continue to drive. Don't hesitate to reach out to Health Advances women's health team with any strategy needs. Susan Posner Jeffrey Abraham Arushi Agarwal Masha Dumanis

Breaking Down Barriers: Innovations in Endocrinology and Diabetes Management https://lnkd.in/eMucf3GJ In the rapidly evolving fields of endocrinology and diabetes, groundbreaking research and technological advancements are transforming how we understand and manage these complex conditions. This blog post explores the latest innovations that are improving patient outcomes, from wearable glucose monitoring devices to novel drug therapies. Join us as we delve into how these developments are empowering patients and healthcare providers to tackle diabetes and endocrine disorders more effectively than ever before #Endocrinology #Diabetes #Diabetesmanagement #Glucosemonitoring #Endocrinedisorders #Innovativetherapies #Patientoutcomes #Medicaltechnology #Diabetesresearch #Hormonalhealth

New publication from our R&D department! In this publication, our R&D team investigated whether testing a biochemical and/or biophysical marker for preterm preeclampsia in the first trimester is cost effective in the Netherlands. The risk of preterm preeclampsia can be significantly reduced by starting acetylsalicylic acids ≤16 weeks of gestational age. Recent studies showed that the predicative models based on maternal risk factors could be improved by including test results of a biochemical/physical marker. When compared to the baseline strategy, the test strategy was estimated to save almost 4 million euros per year on a national scale, and at the same time this would prevent an additional 228 preterm preeclampsia cases. The study showed that a first trimester test strategy to screen for preterm preeclampsia in the first trimester is potentially cost-effective in the Dutch healthcare setting. Visit https://lnkd.in/e4wigyqt if you wish to read the full publication. #Researchanddevelopment #preeclampsia